Drugs / BMS-986325
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05813717 | Apr → Oct 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04684654 | Feb 2021 → Jul 2023 | Sjogren syndrome | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04684654 ↗ |
| Route | Intravenous | “Subcutaneous and Intravenous BMS-986325 Administration” NCT04684654 ↗ |
| Route | Subcutaneous | “Subcutaneous and Intravenous BMS-986325 Administration” NCT04684654 ↗ |